XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Net Revenue $ 64,989,842 $ 45,842,845
Cost of goods sold 7,852,686 6,360,851
Gross profit 57,137,156 39,481,994
Operating expenses    
Selling, general and administrative expenses 56,994,753 45,976,328
Research and development 4,132,425 3,367,032
Depreciation and amortization 3,675,026 2,371,068
Change in fair value of earnout liabilities (3,449,895) 284,746
Total operating expenses 61,352,309 51,999,174
Operating loss (4,215,153) (12,517,180)
Other income (expense)    
Interest expense and other (475,783)
Share of losses from equity method investment (379,633)
Gain (loss) on disposal of investment 251,034 (1,040,311)
Total other income (expense) (224,749) (1,419,944)
Loss before income taxes (4,439,902) (13,937,124)
Income tax benefit 5,844,796
Net loss (4,439,902) (8,092,328)
Less: Net loss attributable to noncontrolling interest (136,705) (154,831)
Net loss attributable to Sanara MedTech shareholders $ (4,303,197) $ (7,937,497)
Net loss per share of common stock, basic $ (0.52) $ (1.00)
Net loss per share of common stock, diluted $ (0.52) $ (1.00)
Weighted average number of common shares outstanding, basic 8,278,949 7,906,794
Weighted average number of common shares outstanding, diluted 8,278,949 7,906,794